Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.

Dang C, Guo H, Najita J, Yardley D, Marcom K, Albain K, Rugo H, Miller K, Ellis M, Shapira I, Wolff AC, Carey LA, Moy B, Groarke J, Moslehi J, Krop I, Burstein HJ, Hudis C, Winer EP, Tolaney SM
JAMA Oncol. 2016 2 (1): 29-36

PMID: 26539793 · PMCID: PMC5654518 · DOI:10.1001/jamaoncol.2015.3709

MeSH Terms (25)

Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols Biomarkers, Tumor Breast Neoplasms Chemotherapy, Adjuvant Disease-Free Survival Drug Administration Schedule Female Humans Middle Aged Neoplasm Staging Paclitaxel Receptor, ErbB-2 Risk Assessment Risk Factors Stroke Volume Time Factors Trastuzumab Treatment Outcome United States Ventricular Dysfunction, Left Ventricular Function, Left Young Adult

Connections (1)

This publication is referenced by other Labnodes entities: